Evotec Signs High Throughput Screening Agreement with Active Biotech
News Mar 12, 2010
Evotec AG has announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.
Evotec will use its expertise and technologies in assay development, high throughput screening (HTS) and surface plasmon resonance (SPR) screening for the identification and validation of novel hits.
In order to maximize the probability of finding high quality medicinal chemistry starting points, Evotec will screen its Lead Discovery Library, a small molecule collection designed for diversity, novelty and quality.
Dorthe da Graça Thrige, Director of Development of Active Biotech, commented: “We have a high regard for Evotec’s expertise and capabilities in assay development and compound screening. In addition, we are impressed with the excellent quality of Evotec’s Lead Discovery Library, which we believe will enable us to generate high quality hits, ensuring a smooth transition to medicinal chemistry activities. Importantly, the hits identified in the HTS will complement the ongoing lead optimization of compounds identified in-house.”
Dr Mark Ashton, Executive Vice President, Business Development of Evotec stated: “We are proud to have been selected by Active Biotech, a leading biotechnology company with advanced drug candidates in the area of immune modulation, to carry out hit identification activities on this important biological target. We look forward to supporting them in their quest to find novel treatments to address immune disorders and cancer.”
Evotec has a unique assay development and screening platform built around proprietary and the latest commercial technologies providing a flexible and high quality approach to lead identification.
No financial details are disclosed.
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018